Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Cellectis S.A. ADR (NQ: CLLS ) 1.894 -0.086 (-4.34%) Streaming Delayed Price Updated: 3:59 PM EDT, Oct 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Cellectis S.A. ADR < Previous 1 2 3 4 5 6 7 Next > Why Is Calyxt (CLXT) Stock Up 140% Today? January 17, 2023 Calyxt (CLXT) stock is rocketing higher on Tuesday after the company signed an all-stock merger agreement with Cibus Global. Via InvestorPlace Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement January 17, 2023 From Cellectis Inc. Via GlobeNewswire 5 Most Expensive Health Care Stocks You Should Worry About January 12, 2023 The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. Via Benzinga Why Tesla Shares Are Trading Lower; Here Are 32 Stocks Moving Premarket January 03, 2023 Gainers Via Benzinga Cellectis Touts Positive Preliminary Data From Two Leukemia Trials December 13, 2022 Via Benzinga Why Horizon Global Shares Are Trading Higher By Over 340%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session January 03, 2023 Gainers Horizon Global Corporation (NYSE: HZN) shares surged 341% to $1.7161 after the company announced it will be acquired by First Brands Group. Via Benzinga Mayflower Bioventures Launches its First Spin-Out, Primera Therapeutics, in Strategic Collaboration with Cellectis to Develop a Gene Editing Platform to Treat Mitochondrial Diseases December 29, 2022 From Cellectis Inc. Via GlobeNewswire Cellectis secures a €40 million credit facility from the European Investment Bank to support its Research, Development and Innovation activities December 28, 2022 From Cellectis Inc. Via GlobeNewswire Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL December 22, 2022 From Cellectis Inc. Via GlobeNewswire Crispr Stock In 2023: Will Down-In-The-Dumps Shares Sparkle Again In 2023? December 22, 2022 Crispr and Vertex are working toward the first submissions for a CRISPR-based product. Via Investor's Business Daily Cellectis Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML December 13, 2022 From Cellectis Inc. Via GlobeNewswire Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022 December 01, 2022 From Cellectis Inc. Via GlobeNewswire Cellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcoming Key Challenges of Targeting Solid Tumors at SITC 2022 November 10, 2022 From Cellectis Inc. Via GlobeNewswire Cellectis Publishes Manuscript in Frontiers Bioengineering and Biotechnology Unveiling Efficient Multitool/Multiplex Gene Engineering combining TALEN® and TALE Base Editors (TALE-BE) November 10, 2022 From Cellectis Inc. Via GlobeNewswire Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2022 November 03, 2022 From Cellectis Inc. Via GlobeNewswire Cellectis to Showcase Clinical Data from AMELI-01 and Preclinical Data from UCARTCS1 at ASH 2022 November 03, 2022 From Cellectis Inc. Via GlobeNewswire Cellectis's Earnings Outlook November 02, 2022 Cellectis (NASDAQ:CLLS) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that Cellectis will... Via Benzinga Cellectis to Report Third Quarter 2022 Financial Results October 27, 2022 From Cellectis Inc. Via GlobeNewswire Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022 October 11, 2022 From Cellectis Inc. Via GlobeNewswire Why Missfresh Shares Are Trading Lower; Here Are 30 Stocks Moving Premarket October 10, 2022 Gainers M-tron Industries, Inc. (NASDAQ: MPTI) rose 57.9% to $24.00 in pre-market trading after surging 10% on Friday. M-tron Industries completed its earlier announced separation from The LGL Group,... Via Benzinga 12 Health Care Stocks Moving In Friday's Pre-Market Session October 07, 2022 Gainers Akanda (NASDAQ:AKAN) stock rose 27.1% to $0.52 during Friday's pre-market session. The company's market cap stands at $16.0 million. Via Benzinga Cellectis to Present Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Supporting Improved Solid Tumor Targeting at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting October 05, 2022 From Cellectis Inc. Via GlobeNewswire Cellectis Appoints Mark Frattini, M.D., Ph.D. as Chief Medical Officer September 28, 2022 From Cellectis Inc. Via GlobeNewswire Why NanoVibronix Shares Surged Over 25%; Here Are 82 Biggest Movers From Friday September 26, 2022 Gainers Golden Sun Education Group Limited (NASDAQ: GSUN) shares surged 92.1% to settle at $52.89 on Friday. Via Benzinga Why Shares Of Oil & Gas Companies Are Trading Lower, Here Are 62 Stocks Moving In Friday's Mid-Day Session September 23, 2022 Gainers Kiromic BioPharma, Inc. (NASDAQ: KRBP) shares jumped 87% to $0.4791. Kiromic BioPharma, said on Sept. 15, that the company received letter from the Nasdaq that co. has been granted 180-day... Via Benzinga 11 Health Care Stocks Moving In Friday's Pre-Market Session September 23, 2022 Gainers Rubius Therapeutics (NASDAQ:RUBY) shares moved upwards by 30.46% to $0.59. The market value of their outstanding shares is at $53.5 million. Via Benzinga Why T2 Biosystems Is Trading Higher By 18%; Here Are 28 Stocks Moving Premarket September 23, 2022 Gainers HHG Capital Corporation (NASDAQ: HHGC) shares rose 42.1% to $14.56 in pre-market trading. Via Benzinga Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study August 02, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga Recap Of Monday's Biotech Catalysts - End Of the Day Summary August 01, 2022 Via Benzinga Cellectis Gets FDA Nod For Initial-Stage Non-Hodgkin Lymphoma Study August 01, 2022 The U.S. Food and Drug Administration (FDA) has announced clearance to Cellectis' (NASDAQ: CLLS) Investigational New Drug (IND) application to initiate a Phase 1/2a clinical trial of UCART20x22 for... Via Benzinga < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.